Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
Metronomic chemotherapy describes the close, regular administration of chemotherapy
drugs at less-toxic doses over prolonged periods of time. In 2015, the results of randomized …
drugs at less-toxic doses over prolonged periods of time. In 2015, the results of randomized …
Bevacizumab: a review of its use in advanced cancer
GM Keating - Drugs, 2014 - Springer
The humanized monoclonal antibody bevacizumab (Avastin®) has been available in the EU
since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to …
since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to …
Diurnal changes in capecitabine clock-controlled metabolism enzymes are responsible for its pharmacokinetics in male mice
YK Akyel, D Ozturk Civelek… - Journal of …, 2023 - journals.sagepub.com
The circadian timing system controls absorption, distribution, metabolism, and elimination
processes of drug pharmacokinetics over a 24-h period. Exposure of target tissues to the …
processes of drug pharmacokinetics over a 24-h period. Exposure of target tissues to the …
Bevacizumab‐enhanced antitumor effect of 5‐fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular …
W Liu, J Zhang, X Yao, C Jiang, P Ni, L Cheng… - Cancer …, 2018 - Wiley Online Library
Bevacizumab (Bv) can be used synergistically with fluoropyrimidine‐based chemotherapy to
treat colorectal cancer. Whether and how it affects the delivery of fluoropyrimidine drugs is …
treat colorectal cancer. Whether and how it affects the delivery of fluoropyrimidine drugs is …
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients
N Matsumoto, Y Kubota, H Ishida, M Sekido… - Cancer Chemotherapy …, 2020 - Springer
Purpose Capecitabine is a prodrug that undergoes metabolism in three steps to form an
active 5-fluorouracil (5-FU). The first step is primarily catalyzed by liver carboxylesterases …
active 5-fluorouracil (5-FU). The first step is primarily catalyzed by liver carboxylesterases …
[HTML][HTML] Clinical pharmacokinetics of capecitabine and its metabolites in colorectal cancer patients
S Alqahtani, R Alzaidi, A Alsultan, A Asiri, Y Asiri… - Saudi Pharmaceutical …, 2022 - Elsevier
Background Capecitabine is one of the fluoropyrimidine anticancer agents which is
extensively used in the management of colorectal cancer. We have noticed a discrepancy …
extensively used in the management of colorectal cancer. We have noticed a discrepancy …
[HTML][HTML] Development and validation of an ecofriendly HPLC-UV method for determination of capecitabine in human plasma: Application to pharmacokinetic studies
S Hassanlou, M Rajabi, M Afshar - South African Journal of …, 2016 - scielo.org.za
A simple, rapid, cost-effective and green high-performance liquid chromatographic assay for
determination of capecitabine in human plasma using a C18 reversed-phase analytical …
determination of capecitabine in human plasma using a C18 reversed-phase analytical …
ArF laser induced fluorescence spectroscopy of the Capecitabine chemodrug
Simultaneous diagnosis and treatment during chemotherapy is an attractive topic in nano-
oncology. Here, Capecitabine, as a well-known chemodrug, demonstrates notable …
oncology. Here, Capecitabine, as a well-known chemodrug, demonstrates notable …
Metronomic and metronomic-like therapies in neuroendocrine tumors–Rationale and clinical perspectives
I Lambrescu, S Fica, D Martins, F Spada, C Cella… - Cancer Treatment …, 2017 - Elsevier
Metronomic therapy is characterized by the administration of regular low doses of certain
drugs with very low toxicity. There have been numerous debates over the empirical …
drugs with very low toxicity. There have been numerous debates over the empirical …
Pharmacodynamic and pharmacokinetic markers for anti-angiogenic cancer therapy: implications for dosing and selection of patients
Angiogenesis is integral to tumour growth and invasion, and is a key target for cancer
therapeutics. However, for many of the licensed indications, only a modest clinical benefit …
therapeutics. However, for many of the licensed indications, only a modest clinical benefit …